NeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia Magazine

Announces Participation in Microdose's Wonderland: Miami on November 8-9, 2021

NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind"), an integrated drug development and wellness company, today announced that NeonMind was ranked third in Psychedelia Magazine's "8 Industry Innovators'' segment within the magazine's inaugural Winter 2022 issue. NeonMind was recognized for its dual approach in bringing psychedelic treatments to patients in need through its anticipated specialty mental health clinic launch and its drug development program for novel obesity treatments

Separately, Rob Tessarolo, President & CEO of NeonMind, will participate in Microdose's Wonderland: Miami, the nation's largest psychedelic medicine business event, which brings together an impressive group of global psychedelic medicine leaders, including scientists and researchers, as well as, investors, entrepreneurs, therapists, patients, and government officials, all championing the growth of the psychedelic medicine industry. Mr. Tessarolo will be participating in one-on-one meetings during the event.

"We are honored to be ranked as a top industry innovator in Psychedelia Magazine, which is a testament to our strategy of pursuing unique modalities across the psychedelic treatment spectrum," said Robert Tessarolo, President & CEO of NeonMind. "As we are advancing quickly across our drug development program and planned specialty clinics launch, we look forward to sharing our updates with industry participants at the Wonderland event in Miami."

Wonderland: Miami will be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November 8-9, 2021.

For more information regarding the event or to schedule a one-on-one meeting with management, please contact KCSA Strategic Communications at NeonMind@KCSA.com.

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind's lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company's second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to www.NeonMindBiosciences.com.

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101

Investor Relations:
KCSA Strategic Communications
Scott Eckstein/Tim Regan
neonmind@kcsa.com
Tel: 212-896-1210

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind's future performance. The use of any of the words "could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

SOURCE: NeonMind Biosciences Inc.